Cellyan Biotechnology
HKPD
4 hedge funds and large institutions have $55.8K invested in Cellyan Biotechnology in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.47% more ownership
Funds ownership: 0% → 0.47% (+0.47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$36.5K |
| 2 |
CS
Clear Street
New York
|
+$27.8K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$26.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$480 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $22.3K | +$36.5K | +20,690 | New |
|
|
CS
2
Clear Street
New York
| $17K | +$27.8K | +15,719 | New |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $16.2K | +$26.5K | +15,000 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $294 | +$480 | +272 | New |
|
HKPD Hedge Fund Activity: Q1 2025 in Review
4 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q1 2025, worth a combined $55.8K.
Buyers outnumbered sellers: 4 funds opened new HKPD positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $36.5K.
- 4 institutional investors held Cellyan Biotechnology (HKPD) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $55.8K of Cellyan Biotechnology stock for Q1 2025.
- 4 funds opened new Cellyan Biotechnology positions in Q1 2025 and 0 closed out, a net change of +4 holders.
- The largest Cellyan Biotechnology buyer in Q1 2025 was Jane Street, an estimated $36.5K added.
Based on aggregated 13F filings for Q1 2025.